Foundry Healthcare CBOperProf Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 43.99% |
2MRK | MERCK & CO INC | Healthcare | $314.90B | 12.47% |
3GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 6.60% |
4BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 4.91% |
5VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 4.88% |
6HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 3.26% |
7REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 2.81% |
8IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 1.77% |
9RVMD | REVOLUTION MEDICINES INC | Healthcare | $39.58B | 1.57% |
10NTRA | NATERA INC | Healthcare | $38.87B | 1.54% |
11ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 1.41% |
12ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 1.37% |
13DXCM | DEXCOM INC | Healthcare | $29.58B | 1.17% |
14ILMN | ILLUMINA INC | Healthcare | $28.24B | 1.12% |
15MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $26.47B | 1.05% |
16INCY | INCYTE CORP | Healthcare | $23.42B | 0.93% |
17UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.90% |
18NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.68% |
19THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 0.67% |
20EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.56% |
21PODD | INSULET CORP | Healthcare | $11.36B | 0.45% |
22ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 0.41% |
23CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.38% |
24HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.37% |
25IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 0.36% |
26IMVT | IMMUNOVANT INC | Healthcare | $8.27B | 0.33% |
27MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $7.25B | 0.29% |
28TXG | 10X GENOMICS INC | Healthcare | $5.55B | 0.22% |
29TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.21% |
30KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.19% |
31ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.17% |
32VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 0.17% |
33DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.16% |
34ALMS | ALUMIS INC | Healthcare | $3.65B | 0.14% |
35NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.14% |
36RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 0.14% |
37IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.13% |
38RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.11% |
39CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.77B | 0.11% |
40KOD | KODIAK SCIENCES INC | Healthcare | $2.67B | 0.11% |
41NRIX | NURIX THERAPEUTICS INC | Healthcare | $2.40B | 0.10% |
42BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.09% |
43BHVN | BIOHAVEN LTD | Healthcare | $2.32B | 0.09% |
44CDNA | CAREDX INC | Healthcare | $2.05B | 0.08% |
45SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $2.02B | 0.08% |
46HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.08% |
47VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $1.86B | 0.07% |
48SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.07% |
49IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.07% |
50ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.07% |
51VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.06% |
52NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.06% |
53MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.45B | 0.06% |
54NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.05% |
55XNCR | XENCOR INC | Healthcare | $1.30B | 0.05% |
56INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.05% |
57MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.05% |
58EYPT | EYEPOINT INC | Healthcare | $1.12B | 0.04% |
59FBRX | FORTE BIOSCIENCES INC | Healthcare | $1.00B | 0.04% |
60VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.04% |
61ANNX | ANNEXON INC | Healthcare | $950M | 0.04% |
62AURA | AURA BIOSCIENCES INC | Healthcare | $723M | 0.03% |
63PHR | PHREESIA INC | Healthcare | $662M | 0.03% |
64FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.02% |
65NPCE | NEUROPACE INC | Healthcare | $548M | 0.02% |
66ARVN | ARVINAS INC | Healthcare | $517M | 0.02% |
67RGNX | REGENXBIO INC | Healthcare | $511M | 0.02% |
68NVCT | NUVECTIS PHARMA INC | Healthcare | $508M | 0.02% |
69DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.02% |
70PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.02% |
71CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.02% |
72ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.02% |
73STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.02% |
74UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.02% |
75CV | CAPSOVISION INC | Healthcare | $335M | 0.01% |
76FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.01% |
77QTTB | Q32 BIO INC | Healthcare | $255M | 0.01% |
78ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.01% |
79GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $240M | 0.01% |
80SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.01% |
81KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.01% |
82AGEN | AGENUS INC | Healthcare | $209M | 0.01% |
83DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.01% |
84ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.01% |
85CRBP | CORBUS PHARMACEUTICALS HOLDINGS INC | Healthcare | $167M | 0.01% |
86PMN | PROMIS NEUROSCIENCES INC | Healthcare | $136M | 0.01% |
87VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.01% |
88AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.01% |
89CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.00% |
90CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
91ACET | ADICET BIO INC | Healthcare | $76M | 0.00% |
92ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.00% |
93XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $2.52T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 69% toward Growth. +1% unclassified (12 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual51.9%Margin-23.1%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual44.0%Margin-19.0%
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 44.0% | -16.3% |
| 3 yearsp.a. | 19.3% | 0.9% |
| 5 yearsp.a. | 12.2% | 10.8% |
| 10 yearsp.a. | 12.0% | 8.6% |
| Since inceptionp.a. | 9.8% | 4.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 14.4% | -8.5% |
| 2025 | 23.8% | -23.2% |
| 2024 | 11.0% | 23.4% |
| 2023 | 8.5% | 3.3% |
| 2022 | 7.2% | 59.3% |
| 2021 | 9.0% | 34.5% |
| 2020 | 17.7% | -1.1% |
| 2019 | 21.9% | -8.5% |
| 2018 | 3.7% | 15.3% |
| 2017 | 15.1% | 12.3% |
| 2016 | -14.6% | 4.8% |
| 2015 | 9.6% | 6.4% |
| 2014 | 34.0% | 10.8% |
| 2013 | 49.3% | -0.2% |
| 2012 | 22.2% | 6.0% |
| 2011 | 22.0% | 26.8% |
| 2010 | 4.7% | -14.6% |
| 2009 | 14.7% | -14.2% |
| 2008 | -5.9% | 40.4% |
| 2007 | 0.1% | -18.9% |
| 2006 | 5.6% | 1.8% |
| 2005 | 9.4% | 18.6% |
| 2004 | 3.7% | -9.9% |
| 2003 | 10.1% | -19.9% |
| 2002 | -21.6% | 2.9% |
| 2001 | -14.3% | 2.1% |
| 2000 | 42.2% | 0.3% |
| 1999 | -3.6% | 22.2% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare CBOperProf Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a CBOperProf signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.